Acetyl Sulfisoxazole
The metabolism of Irinotecan can be decreased when combined with Acetyl sulfisoxazole.
Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Irinotecan.
Adenine
The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Adenine.
Advertisement
Amiodarone
The serum concentration of Irinotecan can be increased when it is combined with Amiodarone.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Irinotecan.
Anhydrous Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Irinotecan.
Advertisement
Anthrax immune globulin, human
The risk or severity of adverse effects can be increased when Irinotecan is combined with Anthrax immune globulin human.
Apalutamide
The serum concentration of Irinotecan can be decreased when it is combined with Apalutamide.
Aprepitant
The serum concentration of Irinotecan can be increased when it is combined with Aprepitant.
Advertisement
Asunaprevir
The serum concentration of Asunaprevir can be increased when it is combined with Irinotecan.
Atazanavir
The serum concentration of Irinotecan can be increased when it is combined with Atazanavir.
Atomoxetine
The metabolism of Irinotecan can be decreased when combined with Atomoxetine.
Atorvastatin
The risk or severity of adverse effects can be increased when Irinotecan is combined with Atorvastatin.
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Irinotecan.
BCG, Live, Connaught Strain
The risk or severity of adverse effects can be increased when Irinotecan is combined with Bacillus calmette-guerin substrain connaught live antigen.
BCG, Live, Tice Strain
The risk or severity of adverse effects can be increased when Irinotecan is combined with Bacillus calmette-guerin substrain tice live antigen.
Bevacizumab
The risk or severity of adverse effects can be increased when Bevacizumab is combined with Irinotecan.
Bevacizumab-Awwb
The risk or severity of adverse effects can be increased when Bevacizumab is combined with Irinotecan.
Boceprevir
The serum concentration of Irinotecan can be increased when it is combined with Boceprevir.
Bortezomib
The metabolism of Irinotecan can be decreased when combined with Bortezomib.
Bosentan
The serum concentration of Irinotecan can be decreased when it is combined with Bosentan.
Bosentan Anhydrous
The serum concentration of Irinotecan can be decreased when it is combined with Bosentan.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Irinotecan.
Bosutinib monohydrate
The serum concentration of Bosutinib can be increased when it is combined with Irinotecan.
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Irinotecan.
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Irinotecan.
Cabergoline
The risk or severity of adverse effects can be increased when Cabergoline is combined with Irinotecan.
Carbamazepine
The serum concentration of Irinotecan can be decreased when it is combined with Carbamazepine.
Ceritinib
The serum concentration of Irinotecan can be increased when it is combined with Ceritinib.
Cerivastatin
The serum concentration of Cerivastatin can be increased when it is combined with Irinotecan.
Citalopram
The metabolism of Irinotecan can be decreased when combined with Citalopram.
Clarithromycin
The serum concentration of Irinotecan can be increased when it is combined with Clarithromycin.
Clemastine
The metabolism of Irinotecan can be decreased when combined with Clemastine.
Clopidogrel
The metabolism of Irinotecan can be decreased when combined with Clopidogrel.
Clotrimazole
The metabolism of Irinotecan can be decreased when combined with Clotrimazole.
Clozapine
The risk or severity of adverse effects can be increased when Irinotecan is combined with Clozapine.
Cobicistat
The serum concentration of Irinotecan can be increased when it is combined with Cobicistat.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Irinotecan.
Crizotinib
The metabolism of Irinotecan can be decreased when combined with Crizotinib.
Curcumin
The serum concentration of Irinotecan can be increased when it is combined with Curcumin.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Irinotecan.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Irinotecan.
Cyclosporine
The metabolism of Irinotecan can be decreased when combined with Cyclosporine.
Dabrafenib
The serum concentration of Irinotecan can be decreased when it is combined with Dabrafenib.
Darunavir
The serum concentration of Irinotecan can be increased when it is combined with Darunavir.
Dasatinib
The serum concentration of Irinotecan can be increased when it is combined with Dasatinib.
Dasatinib Anhydrous
The serum concentration of Irinotecan can be increased when it is combined with Dasatinib.
Deferasirox
The serum concentration of Irinotecan can be decreased when it is combined with Deferasirox.
Delavirdine
The metabolism of Irinotecan can be decreased when combined with Delavirdine.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Irinotecan.
Desipramine
The metabolism of Irinotecan can be decreased when combined with Desipramine.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Irinotecan.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Irinotecan.
Digoxin
Digoxin may decrease the cardiotoxic activities of Irinotecan.
Dihydroergocornine
The risk or severity of adverse effects can be increased when Dihydroergocornine is combined with Irinotecan.
Dihydroergocristine
The risk or severity of adverse effects can be increased when Dihydroergocristine is combined with Irinotecan.
Dihydroergotamine
The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Irinotecan.
Diltiazem
The metabolism of Irinotecan can be decreased when combined with Diltiazem.
Dipyrone
The risk or severity of myelosuppression can be increased when Metamizole is combined with Irinotecan.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Irinotecan.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Irinotecan.
Doxorubicin
The metabolism of Irinotecan can be decreased when combined with Doxorubicin.
Doxorubicin Hydrochloride
The metabolism of Irinotecan can be decreased when combined with Doxorubicin.
Doxycycline
The metabolism of Irinotecan can be decreased when combined with Doxycycline.
Doxycycline Anhydrous
The metabolism of Irinotecan can be decreased when combined with Doxycycline.
Dronedarone
The metabolism of Irinotecan can be decreased when combined with Dronedarone.
Eltrombopag
The serum concentration of Irinotecan can be increased when it is combined with Eltrombopag.
Enasidenib
The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Enasidenib.
Enzalutamide
The serum concentration of Irinotecan can be decreased when it is combined with Enzalutamide.
Ergonovine
The risk or severity of adverse effects can be increased when Ergonovine is combined with Irinotecan.
Ergotamine
The risk or severity of adverse effects can be increased when Ergotamine is combined with Irinotecan.
Erlotinib
The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Erlotinib.
Ertugliflozin
The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Ertugliflozin.
Erythromycin
The metabolism of Irinotecan can be decreased when combined with Erythromycin.
Fingolimod
Irinotecan may increase the immunosuppressive activities of Fingolimod.
Fluconazole
The metabolism of Irinotecan can be decreased when combined with Fluconazole.
Flunitrazepam
The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Flunitrazepam.
Fluvastatin
The serum concentration of Fluvastatin can be increased when it is combined with Irinotecan.
Fluvoxamine
The metabolism of Irinotecan can be decreased when combined with Fluvoxamine.
Fosamprenavir
The metabolism of Irinotecan can be decreased when combined with Fosamprenavir.
Fosaprepitant
The serum concentration of Irinotecan can be increased when it is combined with Fosaprepitant.
Fosphenytoin
The serum concentration of Irinotecan can be decreased when it is combined with Fosphenytoin.
Fostamatinib
The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Fostamatinib.
Fusidate
The serum concentration of Irinotecan can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Irinotecan can be increased when it is combined with Fusidic Acid.
Gemfibrozil
The serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Gemfibrozil.
Glecaprevir
The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Glecaprevir.
Hepatitis A Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Irinotecan is combined with Hepatitis A Vaccine.
Hepatitis B Surface Antigen Vaccine
The risk or severity of adverse effects can be increased when Irinotecan is combined with Hepatitis B Vaccine (Recombinant).
Hypoxis hemerocallidea root extract
The therapeutic efficacy of Irinotecan can be decreased when used in combination with St. John's Wort.
Ibrutinib
The serum concentration of Ibrutinib can be increased when it is combined with Irinotecan.
Idelalisib
The serum concentration of Irinotecan can be increased when it is combined with Idelalisib.
Imatinib
The metabolism of Irinotecan can be decreased when combined with Imatinib.
Indinavir
The serum concentration of Irinotecan can be increased when it is combined with Indinavir.
INDINAVIR ANHYDROUS
The serum concentration of Irinotecan can be increased when it is combined with Indinavir.
Indomethacin
The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Indomethacin.
Isavuconazole
The serum concentration of Irinotecan can be increased when it is combined with Isavuconazole.
Isavuconazonium
The metabolism of Irinotecan can be decreased when combined with Isavuconazonium.
Isradipine
The metabolism of Irinotecan can be decreased when combined with Isradipine.
Itraconazole
The serum concentration of Irinotecan can be increased when it is combined with Itraconazole.
Ivacaftor
The serum concentration of Irinotecan can be increased when it is combined with Ivacaftor.
Ketoconazole
The serum concentration of Irinotecan can be increased when it is combined with Ketoconazole.
Leflunomide
The risk or severity of adverse effects can be increased when Irinotecan is combined with Leflunomide.
Lipegfilgrastim
Irinotecan may increase the myelosuppressive activities of Lipegfilgrastim.
Lisuride
The risk or severity of adverse effects can be increased when Lisuride is combined with Irinotecan.
Lopinavir
The serum concentration of Irinotecan can be increased when it is combined with Lopinavir.
Lovastatin
The serum concentration of Lovastatin can be increased when it is combined with Irinotecan.
Luliconazole
The serum concentration of Irinotecan can be increased when it is combined with Luliconazole.
Lumacaftor
The serum concentration of Irinotecan can be decreased when it is combined with Lumacaftor.
Metergoline
The risk or severity of adverse effects can be increased when Metergoline is combined with Irinotecan.
Methylergonovine
The risk or severity of adverse effects can be increased when Methylergometrine is combined with Irinotecan.
Methysergide
The risk or severity of adverse effects can be increased when Methysergide is combined with Irinotecan.
Mifepristone
The serum concentration of Irinotecan can be increased when it is combined with Mifepristone.
Mitotane
The serum concentration of Irinotecan can be decreased when it is combined with Mitotane.
Natalizumab
The risk or severity of adverse effects can be increased when Irinotecan is combined with Natalizumab.
Nefazodone
The serum concentration of Irinotecan can be increased when it is combined with Nefazodone.
Nelfinavir
The serum concentration of Irinotecan can be increased when it is combined with Nelfinavir.
Netupitant
The serum concentration of Irinotecan can be increased when it is combined with Netupitant.
Nevirapine
The serum concentration of Irinotecan can be decreased when it is combined with Nevirapine.
Nicergoline
The risk or severity of adverse effects can be increased when Nicergoline is combined with Irinotecan.
Nilotinib
The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Nilotinib.
Ocrelizumab
Ocrelizumab may increase the immunosuppressive activities of Irinotecan.
Olaparib
The metabolism of Irinotecan can be decreased when combined with Olaparib.
Osimertinib
The serum concentration of Irinotecan can be increased when it is combined with Osimertinib.
Ouabain
Ouabain may decrease the cardiotoxic activities of Irinotecan.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Irinotecan.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Irinotecan.
Palbociclib
The serum concentration of Irinotecan can be increased when it is combined with Palbociclib.
Paroxetine
The metabolism of Irinotecan can be decreased when combined with Paroxetine.
Pazopanib
The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Pazopanib.
Pentobarbital
The serum concentration of Irinotecan can be decreased when it is combined with Pentobarbital.
Pergolide
The risk or severity of adverse effects can be increased when Pergolide is combined with Irinotecan.
Phenobarbital
The serum concentration of Irinotecan can be decreased when it is combined with Phenobarbital.
Phenytoin
The serum concentration of Irinotecan can be decreased when it is combined with Phenytoin.
Pibrentasvir
The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Pibrentasvir.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Irinotecan.
Pitavastatin
The serum concentration of Pitavastatin can be increased when it is combined with Irinotecan.
Posaconazole
The serum concentration of Irinotecan can be increased when it is combined with Posaconazole.
Pravastatin
The serum concentration of Pravastatin can be increased when it is combined with Irinotecan.
Primidone
The serum concentration of Irinotecan can be decreased when it is combined with Primidone.
Propofol
The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Propofol.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Irinotecan.
Quazepam
The serum concentration of Irinotecan can be increased when it is combined with Quazepam.
Rabies Immune Globulin, Human
The risk or severity of adverse effects can be increased when Irinotecan is combined with Human rabies virus immune globulin.
Rabies Virus Vaccine Flury-Lep Strain
The risk or severity of adverse effects can be increased when Irinotecan is combined with Rabies virus inactivated antigen, A.
Ranolazine
The serum concentration of Irinotecan can be increased when it is combined with Ranolazine.
Regorafenib
The serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Regorafenib.
Rifabutin
The serum concentration of Irinotecan can be decreased when it is combined with Rifabutin.
Rifampin
The serum concentration of Irinotecan can be decreased when it is combined with Rifampicin.
Rifapentine
The serum concentration of Irinotecan can be decreased when it is combined with Rifapentine.
Rilpivirine
The serum concentration of Rilpivirine can be increased when it is combined with Irinotecan.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Irinotecan.
Rolapitant
The serum concentration of Irinotecan can be increased when it is combined with Rolapitant.
Rosuvastatin
The serum concentration of Rosuvastatin can be increased when it is combined with Irinotecan.
ROTAVIRUS VACCINE, LIVE
The risk or severity of adverse effects can be increased when Irinotecan is combined with Rotavirus Vaccine.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The risk or severity of adverse effects can be increased when Irinotecan is combined with Rubella virus vaccine.
Rucaparib
The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Rucaparib.
Salmonella enterica subsp. enterica serovar typhi
The risk or severity of adverse effects can be increased when Irinotecan is combined with Salmonella typhi ty21a live antigen.
Saquinavir
The serum concentration of Irinotecan can be increased when it is combined with Saquinavir.
Saquinavir Mesylate
The serum concentration of Irinotecan can be increased when it is combined with Saquinavir.
Sarilumab
The therapeutic efficacy of Irinotecan can be decreased when used in combination with Sarilumab.
Sertraline
The metabolism of Irinotecan can be decreased when combined with Sertraline.
Sildenafil
The metabolism of Irinotecan can be decreased when combined with Sildenafil.
Siltuximab
The serum concentration of Irinotecan can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Irinotecan can be increased when it is combined with Simeprevir.
Simvastatin
The serum concentration of Simvastatin can be increased when it is combined with Irinotecan.
sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Irinotecan.
Sorafenib
The serum concentration of Irinotecan can be increased when it is combined with Sorafenib.
ST. JOHN'S WORT EXTRACT
The therapeutic efficacy of Irinotecan can be decreased when used in combination with St. John's Wort.
Sulfisoxazole
The metabolism of Irinotecan can be decreased when combined with Sulfisoxazole.
Tacrolimus
Tacrolimus may increase the immunosuppressive activities of Irinotecan.
Telaprevir
The serum concentration of Irinotecan can be increased when it is combined with Telaprevir.
Telithromycin
The serum concentration of Irinotecan can be increased when it is combined with Telithromycin.
Teriflunomide
The serum concentration of Irinotecan can be increased when it is combined with Teriflunomide.
Tetanus Toxoid Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Irinotecan is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Thiotepa
The metabolism of Irinotecan can be decreased when combined with Thiotepa.
Ticlopidine
The metabolism of Irinotecan can be decreased when combined with Ticlopidine.
Tocilizumab
The serum concentration of Irinotecan can be decreased when it is combined with Tocilizumab.
Tofacitinib
Irinotecan may increase the immunosuppressive activities of Tofacitinib.
Tolvaptan
The serum concentration of Tolvaptan can be increased when it is combined with Irinotecan.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Irinotecan.
Typhoid Vaccine Live Ty21a
The risk or severity of adverse effects can be increased when Irinotecan is combined with Salmonella typhi ty21a live antigen.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The risk or severity of adverse effects can be increased when Irinotecan is combined with Salmonella typhi ty2 vi polysaccharide antigen.
Varicella Virus Vaccine Live (Oka-Merck) strain
The risk or severity of adverse effects can be increased when Irinotecan is combined with Varicella Zoster Vaccine (Live/Attenuated).
Vemurafenib
The serum concentration of Irinotecan can be increased when it is combined with Vemurafenib.
Venlafaxine
The metabolism of Irinotecan can be decreased when combined with Venlafaxine.
Verapamil
The metabolism of Irinotecan can be decreased when combined with Verapamil.
Voriconazole
The serum concentration of Irinotecan can be increased when it is combined with Voriconazole.
Yellow Fever Vaccine
The risk or severity of adverse effects can be increased when Irinotecan is combined with Yellow Fever Vaccine.
Yellow-Fever Virus Vaccine, 17D-204 strain
The risk or severity of adverse effects can be increased when Irinotecan is combined with Yellow Fever Vaccine.
Ziprasidone
The metabolism of Irinotecan can be decreased when combined with Ziprasidone.
